Abstract Number: 1342 • 2019 ACR/ARP Annual Meeting
Identification of Heterogenous Treatment Response Trajectories to anti-IL6 Receptor Treatment in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a complex autoimmune disease with a fluctuating course of disease activity and progression. Although treatments have improved substantially in recent…Abstract Number: 1963 • 2019 ACR/ARP Annual Meeting
Combining Clinical and Candidate Gene Data into a Risk Score for Azathioprine-Associated Leukopenia in Routine Clinical Practice
Background/Purpose: Azathioprine is a widely-used drug for the treatment of rheumatic diseases, inflammatory bowel disease, and for organ transplantation. However, treatment is often limited by…Abstract Number: 2780 • 2019 ACR/ARP Annual Meeting
Identification of SLE Subgroups at Risk for Poor Outcomes After Hydroxychloroquine Taper or Discontinuation
Background/Purpose: The risks and benefits of long-term hydroxychloroquine (HCQ) use in systemic lupus erythematosus (SLE), versus tapering or stopping, remain uncertain. We aimed to identify predictors of…Abstract Number: 2915 • 2019 ACR/ARP Annual Meeting
Machine-learning Classification Identifies a Subset of Patients That Improve on Abatacept via Modulation of a CD28-Related Pathway
Background/Purpose: We analyzed a phase 2 study designed to assess the efficacy of abatacept in patients with diffuse Systemic Sclerosis (SSc). In this work, we…Abstract Number: L08 • 2018 ACR/ARHP Annual Meeting
High Baseline Serum IL-6 Identifies a Subgroup of Rheumatoid Arthritis Patients with Rapid Joint Damage and Clinical Progression and Predicts Increased Sarilumab Treatment Response
Background/Purpose: Clinical application of biomarkers to predict response to therapy is the next frontier in RA. Despite the key role of IL-6 in RA, the…Abstract Number: 919 • 2018 ACR/ARHP Annual Meeting
A Machine Learning Classifier for Assigning Individual Patients with Systemic Sclerosis to Intrinsic Molecular Subsets
Background/Purpose: High-throughput gene expression profiling of skin biopsies from patients with systemic sclerosis (SSc) has identified four “intrinsic” gene expression subsets conserved across multiple cohorts…Abstract Number: 1494 • 2018 ACR/ARHP Annual Meeting
Predictors of Persistence to Methotrexate Treatment in RA – Assessment of Different Modelling Approaches
Background/Purpose: As a step towards personalized medicine, we seek to identify patients with new-onset RA who are likely to remain well on MTX monotherapy. Patients…Abstract Number: 1876 • 2018 ACR/ARHP Annual Meeting
Machine Learning Classification of Peripheral Blood Gene Expression Identifies a Subset of Patients with Systemic Sclerosis Most Likely to Show Clinical Improvement in Response to Hematopoietic Stem Cell Transplant
Background/Purpose: The SCOT (Scleroderma: Cyclophosphamide or Transplantation) trial (Sullivan K. et al, 2018) demonstrated the clinical benefit of hematopoietic stem cell transplant (HSCT) compared to…Abstract Number: 2048 • 2018 ACR/ARHP Annual Meeting
In Vitro Proof-of-Concept of Pathobiology-Guided Therapy in Immune Mediated Inflammatory Arthritis
Background/Purpose: Immune mediated inflammatory arthritis are very heterogeneous diseases including rheumatoid arthritis (RA), psoriatic arthritis (PsA) and spondyloarthritis (SpA). The available biological and targeted synthetic…Abstract Number: 166 • 2017 ACR/ARHP Annual Meeting
Integrative Systems Biology Approach Identifies Key Transcription Factors and Novel Rheumatoid Arthritis (RA) and Individualized Therapeutic Targets
Background/Purpose: The search for novel targets in RA requires novel computational methods and in silicosystems to identify non-obvious pathways that account for the diversity of…Abstract Number: 1016 • 2017 ACR/ARHP Annual Meeting
The Genetic Biomarkers to Predicting Response of TNF Inhibitors Treatment in Rheumatoid Arthritis
Background/Purpose: Although pharmacogenetic studies of TNF inhibitors (TNFi) response presented the estimates of high heritability, only few loci with suggestive weak association as biomarkers for…Abstract Number: 1022 • 2017 ACR/ARHP Annual Meeting
A Personalized Medicine Approach to Improve the Prediction of Azathioprine-Induced Pancreatic Injury: Preliminary Results
Background/Purpose: Azathioprine (AZA) is used to treat rheumatic diseases and to prevent transplant rejection. There is marked variability in toxicity to azathioprine; one such toxicity…Abstract Number: 1672 • 2017 ACR/ARHP Annual Meeting
Cytokines and Autoantibody Cluster-Interaction in Systemic Lupus Erythematosus. a Systems Medicine Approach
Background/Purpose: Evidence supports the existence of different sub-phenotypes and the pivotal role of cytokines and autoantibodies in systemic lupus erythematosus (SLE). Cytokines interact in a…Abstract Number: 2429 • 2017 ACR/ARHP Annual Meeting
Towards Precision Medicine in Rheumatoid Arthritis (RA): Trans-Ethnic Analysis and Prioritization of SNPs in the AFF3 Locus
Background/Purpose: Genetic variants in AFF3 have been associated with RA, including in our GWAS and ImmunoChip analyses of African-Americans (610 RA; 1543 controls). Likewise, an…Abstract Number: 2600 • 2017 ACR/ARHP Annual Meeting
Plasma Cell and T-Cell Activity Downregulation during MMF Therapy in SLE May be Necessary for Successful Immunosuppression
Background/Purpose: MMF is a key therapy for moderate to severe SLE. MMF inhibits inosine monophosphate dehydrogenase, an enzyme needed in nucleotide synthesis required for lymphocyte…
ACR Meeting Abstracts